CA2769991C - Met inhibitors for enhancing radiotherapy efficacy - Google Patents
Met inhibitors for enhancing radiotherapy efficacy Download PDFInfo
- Publication number
- CA2769991C CA2769991C CA2769991A CA2769991A CA2769991C CA 2769991 C CA2769991 C CA 2769991C CA 2769991 A CA2769991 A CA 2769991A CA 2769991 A CA2769991 A CA 2769991A CA 2769991 C CA2769991 C CA 2769991C
- Authority
- CA
- Canada
- Prior art keywords
- met
- met inhibitor
- radiotherapy
- polynucleotide
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11158861.2A EP2500036B1 (en) | 2011-03-18 | 2011-03-18 | MET inhibitors for enhancing radiotherapy efficacy |
| EP11158861.2 | 2011-03-18 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2769991A1 CA2769991A1 (en) | 2012-09-18 |
| CA2769991C true CA2769991C (en) | 2018-05-15 |
Family
ID=44260211
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2769991A Active CA2769991C (en) | 2011-03-18 | 2012-03-01 | Met inhibitors for enhancing radiotherapy efficacy |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20120237524A1 (2) |
| EP (1) | EP2500036B1 (2) |
| JP (1) | JP5671487B2 (2) |
| KR (1) | KR101540838B1 (2) |
| CN (1) | CN102688491A (2) |
| AU (1) | AU2012201303B2 (2) |
| BR (1) | BR102012006063B1 (2) |
| CA (1) | CA2769991C (2) |
| CY (1) | CY1115374T1 (2) |
| DK (1) | DK2500036T3 (2) |
| EA (1) | EA028590B1 (2) |
| ES (1) | ES2489475T3 (2) |
| HR (1) | HRP20140729T1 (2) |
| IL (1) | IL218293A (2) |
| MX (1) | MX2012003084A (2) |
| PL (1) | PL2500036T3 (2) |
| PT (1) | PT2500036E (2) |
| RS (1) | RS53468B (2) |
| SG (1) | SG184637A1 (2) |
| SI (1) | SI2500036T1 (2) |
| SM (1) | SMT201400106B (2) |
| ZA (1) | ZA201201992B (2) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
| TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法 |
| IT201800009282A1 (it) * | 2018-10-09 | 2020-04-09 | Metis Prec Medicine Sb Srl | Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi |
| CN110320365B (zh) * | 2019-07-06 | 2022-07-22 | 湖南莱拓福生物科技有限公司 | NF-κB RelA/p65蛋白位点特异性磷酸化诊断试剂盒 |
| US11896682B2 (en) | 2019-09-16 | 2024-02-13 | Regeneron Pharmaceuticals, Inc. | Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereof |
| EP4687905A1 (en) | 2023-03-30 | 2026-02-11 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI310684B (en) * | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
| WO2004072117A2 (en) * | 2003-02-13 | 2004-08-26 | Pharmacia Corporation | Antibodies to c-met for the treatment of cancers |
| KR101254371B1 (ko) * | 2003-07-18 | 2013-05-02 | 암젠 프레몬트 인코포레이티드 | 간세포 성장인자에 결합하는 분리된 항체 |
| HN2004000285A (es) * | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
| CA2638889C (en) * | 2006-02-06 | 2015-06-02 | Metheresis Translational Research S.A. | Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products |
| EP2019116A1 (en) * | 2007-07-26 | 2009-01-28 | Helmholtz-Zentrum für Infektionsforschung GmbH | Inhibitor of the met-receptor and its use |
-
2011
- 2011-03-18 DK DK11158861.2T patent/DK2500036T3/da active
- 2011-03-18 EP EP11158861.2A patent/EP2500036B1/en active Active
- 2011-03-18 ES ES11158861.2T patent/ES2489475T3/es active Active
- 2011-03-18 PT PT111588612T patent/PT2500036E/pt unknown
- 2011-03-18 PL PL11158861T patent/PL2500036T3/pl unknown
- 2011-03-18 RS RS20140404A patent/RS53468B/sr unknown
- 2011-03-18 SI SI201130217T patent/SI2500036T1/sl unknown
-
2012
- 2012-02-22 SG SG2012012514A patent/SG184637A1/en unknown
- 2012-02-23 IL IL218293A patent/IL218293A/en active IP Right Grant
- 2012-02-24 JP JP2012039193A patent/JP5671487B2/ja active Active
- 2012-03-01 CA CA2769991A patent/CA2769991C/en active Active
- 2012-03-02 AU AU2012201303A patent/AU2012201303B2/en active Active
- 2012-03-13 KR KR1020120025311A patent/KR101540838B1/ko active Active
- 2012-03-13 MX MX2012003084A patent/MX2012003084A/es active IP Right Grant
- 2012-03-16 BR BR102012006063-9A patent/BR102012006063B1/pt active IP Right Grant
- 2012-03-16 CN CN2012100803665A patent/CN102688491A/zh active Pending
- 2012-03-16 EA EA201200329A patent/EA028590B1/ru not_active IP Right Cessation
- 2012-03-16 ZA ZA2012/01992A patent/ZA201201992B/en unknown
- 2012-03-19 US US13/423,830 patent/US20120237524A1/en not_active Abandoned
-
2014
- 2014-07-24 CY CY20141100561T patent/CY1115374T1/el unknown
- 2014-07-29 HR HRP20140729AT patent/HRP20140729T1/hr unknown
- 2014-07-31 SM SM201400106T patent/SMT201400106B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CY1115374T1 (el) | 2017-01-04 |
| AU2012201303A1 (en) | 2012-10-04 |
| US20120237524A1 (en) | 2012-09-20 |
| SG184637A1 (en) | 2012-10-30 |
| EA028590B1 (ru) | 2017-12-29 |
| CA2769991A1 (en) | 2012-09-18 |
| CN102688491A (zh) | 2012-09-26 |
| KR101540838B1 (ko) | 2015-08-06 |
| HRP20140729T1 (hr) | 2014-08-29 |
| RS53468B (sr) | 2014-12-31 |
| BR102012006063A8 (pt) | 2022-11-08 |
| PT2500036E (pt) | 2014-08-25 |
| IL218293A (en) | 2016-06-30 |
| AU2012201303B2 (en) | 2013-11-07 |
| DK2500036T3 (da) | 2014-08-04 |
| KR20120106582A (ko) | 2012-09-26 |
| EA201200329A3 (ru) | 2013-01-30 |
| ES2489475T3 (es) | 2014-09-02 |
| HK1174539A1 (en) | 2013-06-14 |
| EP2500036A1 (en) | 2012-09-19 |
| IL218293A0 (en) | 2012-07-31 |
| EP2500036B1 (en) | 2014-05-07 |
| ZA201201992B (en) | 2015-05-27 |
| BR102012006063A2 (pt) | 2021-11-16 |
| BR102012006063B1 (pt) | 2023-03-07 |
| JP2012196206A (ja) | 2012-10-18 |
| JP5671487B2 (ja) | 2015-02-18 |
| SMT201400106B (it) | 2014-11-10 |
| MX2012003084A (es) | 2012-09-17 |
| SI2500036T1 (sl) | 2014-09-30 |
| PL2500036T3 (pl) | 2014-10-31 |
| EA201200329A2 (ru) | 2012-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2769991C (en) | Met inhibitors for enhancing radiotherapy efficacy | |
| CA2736929C (en) | Inhibition of plgf to treat philadelphia chromosome positive leukemia | |
| Guo et al. | FGF19/FGFR4 signaling contributes to hepatocellular carcinoma survival and immune escape by regulating IGF2BP1-mediated expression of PD-L1 | |
| US20230227823A1 (en) | Fmrp and cancer treatment | |
| CN112543809A (zh) | 包含C/EBPα saRNA的组合疗法 | |
| Crose et al. | Receptor tyrosine kinases as therapeutic targets in rhabdomyosarcoma | |
| Denduluri et al. | Circulating biomarkers of bevacizumab activity in patients with breast cancer | |
| US11679100B2 (en) | Methods of enhancing immunity | |
| HK1174539B (en) | Met inhibitors for enhancing radiotherapy efficacy | |
| JP5579699B2 (ja) | 分子標的薬に対する感受性が低下している癌の治療薬および分子標的薬に対する感受性を増強する医薬組成物 | |
| Mongiardi et al. | Cancer Response to Therapy-Induced Senescence: A Matter of Dose and Timing. Cancers 2021, 13, 484 | |
| Kazimova et al. | Identification of Biologically Active Factors in the Ionizing Radiation Regulated Secretome | |
| Rosa | Doctorate Program in Molecular Oncology and Endocrinology Doctorate School in Molecular Medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| EEER | Examination request |
Effective date: 20121224 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD Year of fee payment: 13 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250220 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250220 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250220 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD Year of fee payment: 14 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260223 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260223 |